Yet another phase II, randomized, open‐label study FIRST (NCT01602380) was designed to evaluate fulvestrant 500 mg (n = 102) in comparison with anastrozole 1 mg (n = 103) as first‐line endocrine therapy for postmenopausal women with HR+/HER2− advanced BC.27 The primary outcome of interest for this non‐inferiority trial was clinical benefit rate (CBR), which was similar for fulvestrant and anastrozole (72.5% vs 67.0%; odds ratio, 1.30; 95% CI, 0.72‐2.38; P = 0.385). The gene discussed is ERBB2; the disease is breast cancer.